Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) is set to release its earnings data after the market closes on Monday, May 6th. Analysts expect Tactile Systems Technology to post earnings of ($0.11) per share for the quarter. Tactile Systems Technology has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) last issued its earnings results on Tuesday, February 20th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.25. Tactile Systems Technology had a net margin of 10.39% and a return on equity of 17.08%. The company had revenue of $77.65 million for the quarter, compared to analysts’ expectations of $78.85 million. During the same quarter last year, the company posted $0.29 earnings per share. On average, analysts expect Tactile Systems Technology to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Tactile Systems Technology Stock Down 1.1 %
TCMD stock opened at $14.28 on Friday. The business’s 50-day moving average is $15.30 and its two-hundred day moving average is $14.10. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.99 and a current ratio of 3.54. The company has a market cap of $339.17 million, a price-to-earnings ratio of 11.90 and a beta of 1.23. Tactile Systems Technology has a fifty-two week low of $9.69 and a fifty-two week high of $26.11.
Insider Activity at Tactile Systems Technology
Tactile Systems Technology Company Profile
Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.
See Also
- Five stocks we like better than Tactile Systems Technology
- Buy P&G Now, Before It Sets A New All-Time High
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Insider Buying Explained: What Investors Need to Know
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- EV Stocks and How to Profit from Them
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.